Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

Joseph M L Kaminski, Alexandra L. Hanlon, Daryl Lim Joon, Marvin Meistrich, Paul Hachem, Alan Pollack

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: Androgen deprivation (AD) is frequently combined with radiotherapy (RT); however, the optimal sequence in vivo is currently unknown. Previous published work from our laboratory demonstrated that AD with RT was consistent with at least an additive, and possibly supra-additive, effect with the combined approach. We, therefore, performed additional experiments to elucidate the optimal sequence. Methods and Materials: R3327-G Dunning rat prostate tumor cells were grown s.c. in the flanks of Copenhagen rats. Treatment was initiated when the tumor reached approximately 1 cm3. Temporary AD was performed by a transscrotal orchiectomy followed 14 days later with androgen restoration using s.c. testosterone implants. RT was delivered using 60Co to 7 Gy. Seven groups, including the controls, were analyzed: Group 1, sham control (Day 0: AD + testosterone); 2, AD control (Day 0: AD, Day 14: testosterone); 3, RT alone on Day 7 (Day 0: AD + testosterone, Day 7 RT); 4, RT alone on Day 3 (Day 0: AD + testosterone, Day 3: RT); 5, RT during AD (Day 0: AD, Day 7: RT, Day 14: testosterone); 6, RT before AD (Day 0: RT, Day 3: AD, Day 17: testosterone); and Group 7, RT after AD (Day 0: AD, Day 14: testosterone, Day 17: RT). The doubling times for tumor growth were calculated for the seven groups from the end of treatment plus 1 day. Differences in doubling time were assessed using analysis of variance, with pair-wise comparisons accomplished using post-hoc Bonferroni tests. Results: An analysis of the differences in the tumor volume doubling time as measured from the end of treatment suggests that Groups 1 and 7 were statistically different from the other groups (p = 0.02). As expected, the sham control group had the shortest doubling time at 5.4 days and Group 7 (14 days of AD administered before RT) had the longest doubling time at 32.6 days. The findings were similar even after excluding an outlying doubling time of 85 days from Group 7 (p < 0.0001). To assess the effect of sequencing further, only Groups 5 through 7 (excluding the outlier) were compared in an analysis of variance with post-hoc Bonferroni tests. Group 7 (RT after AD) demonstrated a significantly longer doubling time than Groups 5 and 6 (p = 0.0024). Conclusion: The results suggest that neoadjuvant AD may result in prolonged suppression of tumor growth, even after testosterone replacement.

Original languageEnglish
Pages (from-to)24-28
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume57
Issue number1
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

deprivation
sequencing
Androgens
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Growth
Testosterone
tumors
analysis of variance
rats
Neoplasms
Analysis of Variance

Keywords

  • Cancer
  • Hormones
  • Neoadjuvant
  • Prostate
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. / Kaminski, Joseph M L; Hanlon, Alexandra L.; Joon, Daryl Lim; Meistrich, Marvin; Hachem, Paul; Pollack, Alan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 57, No. 1, 01.09.2003, p. 24-28.

Research output: Contribution to journalArticle

Kaminski, Joseph M L ; Hanlon, Alexandra L. ; Joon, Daryl Lim ; Meistrich, Marvin ; Hachem, Paul ; Pollack, Alan. / Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. In: International Journal of Radiation Oncology Biology Physics. 2003 ; Vol. 57, No. 1. pp. 24-28.
@article{225beb75decc408184b1b895069dffaa,
title = "Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth",
abstract = "Purpose: Androgen deprivation (AD) is frequently combined with radiotherapy (RT); however, the optimal sequence in vivo is currently unknown. Previous published work from our laboratory demonstrated that AD with RT was consistent with at least an additive, and possibly supra-additive, effect with the combined approach. We, therefore, performed additional experiments to elucidate the optimal sequence. Methods and Materials: R3327-G Dunning rat prostate tumor cells were grown s.c. in the flanks of Copenhagen rats. Treatment was initiated when the tumor reached approximately 1 cm3. Temporary AD was performed by a transscrotal orchiectomy followed 14 days later with androgen restoration using s.c. testosterone implants. RT was delivered using 60Co to 7 Gy. Seven groups, including the controls, were analyzed: Group 1, sham control (Day 0: AD + testosterone); 2, AD control (Day 0: AD, Day 14: testosterone); 3, RT alone on Day 7 (Day 0: AD + testosterone, Day 7 RT); 4, RT alone on Day 3 (Day 0: AD + testosterone, Day 3: RT); 5, RT during AD (Day 0: AD, Day 7: RT, Day 14: testosterone); 6, RT before AD (Day 0: RT, Day 3: AD, Day 17: testosterone); and Group 7, RT after AD (Day 0: AD, Day 14: testosterone, Day 17: RT). The doubling times for tumor growth were calculated for the seven groups from the end of treatment plus 1 day. Differences in doubling time were assessed using analysis of variance, with pair-wise comparisons accomplished using post-hoc Bonferroni tests. Results: An analysis of the differences in the tumor volume doubling time as measured from the end of treatment suggests that Groups 1 and 7 were statistically different from the other groups (p = 0.02). As expected, the sham control group had the shortest doubling time at 5.4 days and Group 7 (14 days of AD administered before RT) had the longest doubling time at 32.6 days. The findings were similar even after excluding an outlying doubling time of 85 days from Group 7 (p < 0.0001). To assess the effect of sequencing further, only Groups 5 through 7 (excluding the outlier) were compared in an analysis of variance with post-hoc Bonferroni tests. Group 7 (RT after AD) demonstrated a significantly longer doubling time than Groups 5 and 6 (p = 0.0024). Conclusion: The results suggest that neoadjuvant AD may result in prolonged suppression of tumor growth, even after testosterone replacement.",
keywords = "Cancer, Hormones, Neoadjuvant, Prostate, Radiotherapy",
author = "Kaminski, {Joseph M L} and Hanlon, {Alexandra L.} and Joon, {Daryl Lim} and Marvin Meistrich and Paul Hachem and Alan Pollack",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S0360-3016(03)00539-X",
language = "English",
volume = "57",
pages = "24--28",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

AU - Kaminski, Joseph M L

AU - Hanlon, Alexandra L.

AU - Joon, Daryl Lim

AU - Meistrich, Marvin

AU - Hachem, Paul

AU - Pollack, Alan

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Purpose: Androgen deprivation (AD) is frequently combined with radiotherapy (RT); however, the optimal sequence in vivo is currently unknown. Previous published work from our laboratory demonstrated that AD with RT was consistent with at least an additive, and possibly supra-additive, effect with the combined approach. We, therefore, performed additional experiments to elucidate the optimal sequence. Methods and Materials: R3327-G Dunning rat prostate tumor cells were grown s.c. in the flanks of Copenhagen rats. Treatment was initiated when the tumor reached approximately 1 cm3. Temporary AD was performed by a transscrotal orchiectomy followed 14 days later with androgen restoration using s.c. testosterone implants. RT was delivered using 60Co to 7 Gy. Seven groups, including the controls, were analyzed: Group 1, sham control (Day 0: AD + testosterone); 2, AD control (Day 0: AD, Day 14: testosterone); 3, RT alone on Day 7 (Day 0: AD + testosterone, Day 7 RT); 4, RT alone on Day 3 (Day 0: AD + testosterone, Day 3: RT); 5, RT during AD (Day 0: AD, Day 7: RT, Day 14: testosterone); 6, RT before AD (Day 0: RT, Day 3: AD, Day 17: testosterone); and Group 7, RT after AD (Day 0: AD, Day 14: testosterone, Day 17: RT). The doubling times for tumor growth were calculated for the seven groups from the end of treatment plus 1 day. Differences in doubling time were assessed using analysis of variance, with pair-wise comparisons accomplished using post-hoc Bonferroni tests. Results: An analysis of the differences in the tumor volume doubling time as measured from the end of treatment suggests that Groups 1 and 7 were statistically different from the other groups (p = 0.02). As expected, the sham control group had the shortest doubling time at 5.4 days and Group 7 (14 days of AD administered before RT) had the longest doubling time at 32.6 days. The findings were similar even after excluding an outlying doubling time of 85 days from Group 7 (p < 0.0001). To assess the effect of sequencing further, only Groups 5 through 7 (excluding the outlier) were compared in an analysis of variance with post-hoc Bonferroni tests. Group 7 (RT after AD) demonstrated a significantly longer doubling time than Groups 5 and 6 (p = 0.0024). Conclusion: The results suggest that neoadjuvant AD may result in prolonged suppression of tumor growth, even after testosterone replacement.

AB - Purpose: Androgen deprivation (AD) is frequently combined with radiotherapy (RT); however, the optimal sequence in vivo is currently unknown. Previous published work from our laboratory demonstrated that AD with RT was consistent with at least an additive, and possibly supra-additive, effect with the combined approach. We, therefore, performed additional experiments to elucidate the optimal sequence. Methods and Materials: R3327-G Dunning rat prostate tumor cells were grown s.c. in the flanks of Copenhagen rats. Treatment was initiated when the tumor reached approximately 1 cm3. Temporary AD was performed by a transscrotal orchiectomy followed 14 days later with androgen restoration using s.c. testosterone implants. RT was delivered using 60Co to 7 Gy. Seven groups, including the controls, were analyzed: Group 1, sham control (Day 0: AD + testosterone); 2, AD control (Day 0: AD, Day 14: testosterone); 3, RT alone on Day 7 (Day 0: AD + testosterone, Day 7 RT); 4, RT alone on Day 3 (Day 0: AD + testosterone, Day 3: RT); 5, RT during AD (Day 0: AD, Day 7: RT, Day 14: testosterone); 6, RT before AD (Day 0: RT, Day 3: AD, Day 17: testosterone); and Group 7, RT after AD (Day 0: AD, Day 14: testosterone, Day 17: RT). The doubling times for tumor growth were calculated for the seven groups from the end of treatment plus 1 day. Differences in doubling time were assessed using analysis of variance, with pair-wise comparisons accomplished using post-hoc Bonferroni tests. Results: An analysis of the differences in the tumor volume doubling time as measured from the end of treatment suggests that Groups 1 and 7 were statistically different from the other groups (p = 0.02). As expected, the sham control group had the shortest doubling time at 5.4 days and Group 7 (14 days of AD administered before RT) had the longest doubling time at 32.6 days. The findings were similar even after excluding an outlying doubling time of 85 days from Group 7 (p < 0.0001). To assess the effect of sequencing further, only Groups 5 through 7 (excluding the outlier) were compared in an analysis of variance with post-hoc Bonferroni tests. Group 7 (RT after AD) demonstrated a significantly longer doubling time than Groups 5 and 6 (p = 0.0024). Conclusion: The results suggest that neoadjuvant AD may result in prolonged suppression of tumor growth, even after testosterone replacement.

KW - Cancer

KW - Hormones

KW - Neoadjuvant

KW - Prostate

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0042566204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042566204&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(03)00539-X

DO - 10.1016/S0360-3016(03)00539-X

M3 - Article

C2 - 12909211

AN - SCOPUS:0042566204

VL - 57

SP - 24

EP - 28

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -